P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- Response to ASX query
- LVAD Results Webcast Presentation
- LVAD Trial Results Provide Potential Regulatory Pathway
- MSB Expands Partnership With JCR For Skin Disease
- Completion of Tasly Transaction, and Appendix 3B
Later from Mesoblast
- MSB Draws US$15 Million From Existing Facility
- MSB Licensee Files For Skin Disease Marketing Approval
- MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
- Mesoblast Initiates Rolling Submission of BLA for GvHD
- MSB Provides Q3 Financial Results and Operational Highlights
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast